BCL2 and breast cancer: Our group had previously reported that mir-195 was a circulating biomarker in breast cancer [45] known to act as a tumor suppressor that targets Bcl-2 transcripts in HR+ breast cancers, actively regulating cell proliferation and the cell cycle and also aiding in the suppression of tumorigenicity [46,47,48].